Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-final-clinical-trial-results-superior-safety-combined-with-similar-efficacy-in-the-trial-of-nrx-101-compared-to-lurasidone-in-suicidal-bipolar-depression-302136430.html
https://www.fiercebiotech.com/biotech/despite-trial-miss-nrx-pushes-antidepressant-forward-phase-3-patients-bipolar-depression
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-receives-notice-from-nasdaq-that-the-company-has-demonstrated-compliance-with-the-bid-price-requirement-302120577.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-announces-pricing-of-2-0-million-underwritten-public-offering-of-common-stock-302120498.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-new-data-on-nrx-101-demonstrating-no-damage-to-intestinal-and-vaginal-flora-in-validated-rodent-models-compared-to-standard-antibiotics-potential-implications-for-avoidance-of-c--302119157.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-common-stock-302120123.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-development-of-new-proprietary-formulation-of-htx-100-iv-ketamine-302116345.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-data-lock-of-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302110102.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update-302104468.html
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-preliminary-fourth-quarter-and-full-year-2023-financial-results-and-provides-year-end-highlights-302102518.html